1. Home
  2. ATYR vs EPSN Comparison

ATYR vs EPSN Comparison

Compare ATYR & EPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • EPSN
  • Stock Information
  • Founded
  • ATYR 2005
  • EPSN 2005
  • Country
  • ATYR United States
  • EPSN Canada
  • Employees
  • ATYR N/A
  • EPSN N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • EPSN Oil & Gas Production
  • Sector
  • ATYR Health Care
  • EPSN Energy
  • Exchange
  • ATYR Nasdaq
  • EPSN Nasdaq
  • Market Cap
  • ATYR 126.3M
  • EPSN 121.5M
  • IPO Year
  • ATYR 2015
  • EPSN N/A
  • Fundamental
  • Price
  • ATYR $2.75
  • EPSN $5.80
  • Analyst Decision
  • ATYR Strong Buy
  • EPSN Strong Buy
  • Analyst Count
  • ATYR 4
  • EPSN 1
  • Target Price
  • ATYR $19.25
  • EPSN $7.00
  • AVG Volume (30 Days)
  • ATYR 978.0K
  • EPSN 62.2K
  • Earning Date
  • ATYR 11-07-2024
  • EPSN 11-07-2024
  • Dividend Yield
  • ATYR N/A
  • EPSN 4.22%
  • EPS Growth
  • ATYR N/A
  • EPSN N/A
  • EPS
  • ATYR N/A
  • EPSN 0.24
  • Revenue
  • ATYR $588,000.00
  • EPSN $30,167,901.00
  • Revenue This Year
  • ATYR N/A
  • EPSN N/A
  • Revenue Next Year
  • ATYR $2,057.88
  • EPSN N/A
  • P/E Ratio
  • ATYR N/A
  • EPSN $25.00
  • Revenue Growth
  • ATYR N/A
  • EPSN N/A
  • 52 Week Low
  • ATYR $1.08
  • EPSN $4.70
  • 52 Week High
  • ATYR $2.84
  • EPSN $6.20
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 85.78
  • EPSN 52.61
  • Support Level
  • ATYR $1.83
  • EPSN $5.44
  • Resistance Level
  • ATYR $1.96
  • EPSN $6.19
  • Average True Range (ATR)
  • ATYR 0.14
  • EPSN 0.25
  • MACD
  • ATYR 0.09
  • EPSN -0.00
  • Stochastic Oscillator
  • ATYR 92.31
  • EPSN 47.37

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About EPSN Epsilon Energy Ltd. Common Share

Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.

Share on Social Networks: